Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $20.83

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given a consensus rating of “Buy” by the eight analysts that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $20.83.

Several equities analysts recently issued reports on the company. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Monday, September 30th. Maxim Group raised their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group reduced their target price on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, September 18th. Finally, JMP Securities initiated coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 target price for the company.

Zevra Therapeutics Trading Down 0.4 %

ZVRA opened at $8.96 on Thursday. Zevra Therapeutics has a twelve month low of $3.89 and a twelve month high of $9.04. The firm has a market cap of $471.46 million, a PE ratio of -5.33 and a beta of 1.93. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The firm’s fifty day moving average is $7.91 and its two-hundred day moving average is $6.40.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The business had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period in the previous year, the business posted ($0.15) EPS. Equities research analysts anticipate that Zevra Therapeutics will post -1.63 EPS for the current year.

Institutional Trading of Zevra Therapeutics

Large investors have recently made changes to their positions in the company. Intech Investment Management LLC bought a new stake in Zevra Therapeutics during the third quarter worth $95,000. Simplify Asset Management Inc. bought a new stake in shares of Zevra Therapeutics during the 3rd quarter worth $833,000. Hunter Associates Investment Management LLC acquired a new stake in Zevra Therapeutics in the third quarter valued at about $92,000. International Assets Investment Management LLC grew its position in Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after acquiring an additional 5,940 shares during the last quarter. Finally, IFG Advisors LLC grew its position in Zevra Therapeutics by 41.2% in the third quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock valued at $183,000 after acquiring an additional 7,700 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.